8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A clinical guide to amlodipine's FDA approval history, current compounding regulations, label requirements, and what prescribers and patients need to know about legally obtaining this calcium channel blocker.
A detailed comparison of how the FDA and EMA regulate amlodipine, covering approval history, label differences, post-market surveillance, and what each framework means for prescribers and patients.
A detailed review of amlodipine FAERS safety signals, FDA label warnings, post-market surveillance findings, and clinical trial evidence. prepared by the HealthRX.com Editorial Team.
A complete timeline of amlodipine's FDA approval, label updates, generic entry, and post-market safety data from 1987 NDA filing through 2026.
A complete guide to amlodipine's regulatory history across the FDA, EMA, and major global agencies, including label requirements, black-box warnings, and post-market safety data.
A review of amlodipine besylate prescribing-information changes discussed in the 2020 to 2026 window, what is confirmed against FDA sources, and what still needs primary-source verification.
A complete regulatory history of amlodipine (Norvasc), covering FDA approval, patent litigation, generic entry, labeling updates, and ongoing post-market surveillance.
A complete guide to amlodipine's FDA approval history, current label, post-market safety record, and next-generation calcium channel blocker pipeline as of 2025.